The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of MoonLake Immunotherapeutics (MLTX) Shareholders

Core Viewpoint - The Gross Law Firm is notifying shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) about a class action lawsuit due to alleged misleading statements regarding the company's drug candidate SLK and its comparison to BIMZELX [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 10, 2024, to September 29, 2025, the defendants made materially false and/or misleading statements [3]. - Key allegations include that SLK and BIMZELX share the same molecular targets, and SLK's unique Nanobody structure does not provide superior clinical benefits over BIMZELX [3]. - It is also claimed that SLK's supposed increased tissue penetration does not translate to clinical efficacy, indicating a lack of reasonable basis for positive statements regarding SLK's superiority [3]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is December 15, 2025, and there is no cost or obligation to participate [4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. - The Gross Law Firm emphasizes its commitment to protecting investors' rights and ensuring responsible business practices [5].